SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property insurance provider Lemonade priced the initial public offering above its range.

Legend Capital-backed quantum computing technology developer QuantumCTek has filed to raise up to $102m in an initial public offering in Shanghai.

QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.

The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.

The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.

The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.

SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.

The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.